Chapter Λ · Protein Shape Transformations — The Mini-Beast

Section 1 · UFRJ · Cristália · ANVISAPolylaminin: Brazilian Protein Shape Transformation

Federal University of Rio de Janeiro · ICB · Extracellular Matrix Biology Laboratory

Tatiana Coelho de Sampaio & Karla Menezes

Developed over 25 years at UFRJ, polylaminin is a pH-induced polymer of placental laminin. Soluble laminin monomers are transformed into a stable, biomimetic scaffold that acts as a biological bridge for axonal regrowth after spinal cord injury. Pharmaceutical production: Cristália (Itapira-SP, Brazil). Regulatory: on 5 January 2026 ANVISA approved the start of Phase 1 clinical studies — announced jointly with the Ministry of Health, prioritised through the Innovation Committee under the clinical-research framework of Lei 14.874/2024, and accompanied by an Independent Data Monitoring Committee for real-time outcomes. ANVISA states that there is as yet no timeline for advancing to the next stage; Cristália has publicly projected approval in about two years.

The Operator Chain in the Biochemistry

The polylaminin transformation is read here as following C → K → F → U. Each operator is matched to a physically distinct stage of the polymerisation; the matching is the proposed reading, not a derived or measured identification:

CompressionOp · Laminin concentration

Laminin monomers are compressed and concentrated under acidic conditions. The three chains (α, β, γ) that form the heterotrimer are brought into proximity — conformational space reduced from three disordered chains to one structured cruciform unit. This is the seed.

CurvatureOp · Ca²⁺ drives approach to κ*

Calcium ion addition (CaCl₂ in acetate buffer, 1:1 v/v at the surgical site) drives local curvature reweighting of the protein manifold. The LG globular domains approach the critical curvature threshold — the polymerisation interface accumulates sectional curvature satisfying τ = p_c / κ = 2. Not yet folded. Approaching.

FoldOp · Whitney A₁ at the polymerisation interface

Rank-1 collapse of the protein manifold into a stable 3D scaffold. Heterotrimers connect at their N-terminal short arms at 120° angles — the hexagonal tiling nucleates. This is the Whitney A₁ singularity at the polymerisation interface. The topology changes irreversibly. You cannot un-polymerise by removing calcium. The fold is permanent.

UnfoldOp · The biological G6 Crystal tiles the injury site

The scaffold unfolds axonal growth cones via attractor selection, regenerating neural pathways while conserving global homology. The hexagonal polylaminin network tiles the spinal cord injury site — a biological G6 Crystal, the same hexagonal geometry as Saturn's polar vortex and graphene self-healing. Six regeneration cycles close at g⁶ = 33.

"The same loop that repairs a single carbon lattice, trains an immune network, or births a galaxy now regenerates severed spinal cords. Protein shape transformations are no longer mysterious: they are explicit, computable instances of the universal regeneration operator."

Clinical Results

Animal studies (rats, 2010; dogs, Frontiers in Veterinary Science 2025) showed dramatic recovery — BBB locomotor scores rising from 4.2 to 8.8 after eight weeks in chronic spinal cord injury. A 2024 pre-trial human pilot — 8 patients, medRxiv preprint 10.1101/2024.02.19.24301010, not peer-reviewed — reported return of voluntary motor contraction in 6 of 8 complete SCI patients, with early anti-inflammatory effects. [PRELIMINARY — not peer-reviewed] Compassionate use is a separate track from the trial and is not approval: as of 11 March 2026, 33 patients were authorised under ANVISA's Programa de Uso Compassivo — sponsor Cristália donating doses — against 59 judicial decisions, with a later tranche reported at 38.

The authorised Phase 1 study is deliberately small: five volunteers, aged 18–72, with acute complete thoracic spinal cord injury, treated surgically within 72 hours of the injury. It is a safety study, not an efficacy one, and its conduct is watched by an independent data monitoring committee created alongside the authorisation. No date has been set for Phase 2.

Bruno Drummond, 31, diagnosed with quadriplegia after a 2018 car accident, received a polylaminin injection within 24 hours of injury. He later walked, descended stairs, and danced for the camera — one of the most dramatic recoveries in the pilot cohort. His case was considered a milestone in Brazilian motor rehabilitation.

Status (Book 3 v2, 2026-09-26) — the clinical record, the predictions, and Section 2. PolylamininChecks.lean (kernel-checked, no sorry).

The clinical record, updated. The human pilot is now peer-reviewed: Lima … Coelho-Sampaio, "Intramedullary injection of polymerized laminin in acute traumatic spinal cord injury: a first-in-human pilot study", Spinal Cord, online 4 August 2026 (link). Eight participants with acute complete injury (AIS A, C4–T12); six of eight progressed to AIS C or D; all six survivors regained voluntary motor control; one walks independently. It is single-arm, and the authors state that the design does not allow conclusions about efficacy — some people with complete injuries improve without treatment, which is why a controlled trial matters. The dog study (Frontiers in Veterinary Science 2025) treated six dogs with chronic injuries (4 months to 7 years) and followed them for six months, with no control group; it used the Texas Spinal Cord Injury Scale (2.2 → 3.2) and an open-field scale (1.5 → 3.1), not the BBB scale. The "BBB 4.2 → 8.8 after eight weeks" figure does not come from that study; BBB is the rat scale, so it may belong to the 2010 rat work and needs its source.

The predictions. (1) Prediction 1 sets the critical concentration at one third of "the maximum working concentration". Two protocols with different working concentrations would then predict different thresholds for the same protein, so the prediction measures a lab's choice, not laminin. Laminin's critical concentration for self-assembly has been measured directly, and that is the value to compare with. (2) Prediction 2's bound, T*·log 3, lies strictly between T* and 1.2·T*; its content is the assumed 26-week cycle, and recovery after six months also occurs without treatment, so attribution needs a control group. (3) Prediction 3 concerns an oscillatory six-cycle protocol, but polylaminin is given as a single intramedullary injection in the trials. The axle run-protein-model command and its output are not in TOTOGT/AXLE; the Separation Theorem there still depends on an open obligation.

Section 2, rewritten in v2. Section 2 now presents homeopathy in the SUS as history, with the nanoparticle hypothesis, the evidence debate and the tests that would settle it; the claims of a "topological mechanism" and of one attractor shared with polylaminin, and the "Unified Protocol", were withdrawn.

Operator reading (see The g-series). Polymerisation is where the fold reading can be tested: a critical concentration (K), abrupt network assembly (F), and — if, as the chapter says, the network does not come apart when calcium is removed — hysteresis (U), since assembly and disassembly then happen under different conditions. Status: model, pending those measurements. The clinical recovery is not yet a fold result: without controls, neither abruptness nor persistence can be attributed to the scaffold.

Section 2 · SUS · Since the 1980sHomeopathy in Brazil: the history, a hypothesis, and how to test it

Sistema Único de Saúde · Unified Health System · Brazil

Brazil recognised homeopathy as a medical specialty in 1980, and the SUS formalised it in its National Policy on Integrative and Complementary Practices in 2006. Use is modest: 0.99% nationally in the 2019 PNS survey, more common with higher socioeconomic status, among women, over age 51, and with chronic conditions. This is Brazilian public-health history, and it is stated here as history.

What patients report, and a known explanation

Patients in SUS homeopathy clinics often report feeling better. A well-studied explanation is the context of care: longer consultations, being listened to, and expectation. These context effects are real and measurable, and they matter for community care whatever the remedy.

The nanoparticle hypothesis

Simple dilution arithmetic predicts that nothing remains: a 30C preparation is diluted by a factor of 10⁶⁰, while a mole holds only about 6×10²³ molecules. The nanoparticle hypothesis is the proposed exception. Chikramane and colleagues at IIT Bombay reported nanoparticles of the starting metal in metal-based remedies up to 200C, and proposed that shaking carries particles forward at the surface instead of diluting them (Homeopathy, 2010); a related hypothesis points to silica from glass vials. The weak points are that the key studies appeared mainly in that one journal, independent replication is limited, and contamination from glassware is hard to rule out. Even if confirmed, the presence of material would not by itself show a clinical effect.

The evidence debate

Positive signals: some meta-analyses report small effects — for example Mathie and colleagues' 2014 review of individualised homeopathy — while rating most of the evidence as low quality with a high risk of bias.
Formal national assessments: Australia's NHMRC (2015) found no reliable evidence of effectiveness for any condition; France's Haute Autorité de Santé judged efficacy insufficient in 2019 (HAS), and public reimbursement ended in 2021; the NHS in England stopped routine funding in 2017. Each has a public health system.
Brazilian reports: the Belo Horizonte dengue project (2009–2010) and the COVID-19 centre reports (2020–2021) are observational, not controlled trials, so they cannot separate the remedy from other causes.

How to test it

Is there something there? An independent lab, blinded, compares a 30C remedy with solvent put through the identical shaking in the same glass, and asks whether the starting element appears above that control.
Does it do anything? A randomised, blinded, placebo-controlled trial of one remedy for one outcome, preregistered — the same standard asked of any pharmaceutical drug.
Does intermittent dosing matter? Intermittent versus continuous dosing as two arms of that trial.

Status

The history: fact.
Patient-reported benefit: observed; context effects are a known explanation.
Nanoparticles surviving dilution: hypothesis — reported, not independently established.
Clinical effect beyond placebo: not supported by the strongest assessments; contested.
An advantage for intermittent dosing: untested.

Polylaminin stands on its own evidence, in Section 1. Nothing in this section is evidence about it, and nothing about it is evidence for this section.

Three Falsifiable PredictionsWhat dm³ Predicts for Brazilian Research

Prediction 1 · Polylaminin concentration threshold

The stability radius^{[Ch 10]} ε₀ = 1/3 predicts that the critical polylaminin concentration for stable hexagonal network formation is 1/3 of the maximum working concentration. At 100 μg/mL (Frontiers 2025 protocol), stable tiling requires a minimum of 33 μg/mL. Below this threshold, the network fragments. Above 3× (300 μg/mL), over-concentration disrupts the hexagonal geometry. Falsified if: stable networks form below 33 μg/mL or concentration shows no threshold behaviour.

Prediction 2 · Recovery time scaling

In any dm³ biological system, recovery time after a fold event scales as T_rec ≤ T* · log 3. For spinal cord injury with polylaminin: T* ≈ 26 weeks (full regeneration cycle), T_rec ≤ 26 × log 3 ≈ 28.6 weeks. The 2025 dog study (6-month follow-up) and 2024 human preprint should show maximal recovery within this window. Falsified if: significant additional recovery occurs after week 29 that is attributable to the polylaminin scaffold rather than natural recovery.

Prediction 3 · Oscillatory protocol superiority

Intermittent oscillatory administration (dose → fold → rest → unfold, 6 cycles) outperforms equivalent total-dose continuous administration in both polylaminin scaffold deployment and SUS oscillatory protocols. The dm³ framework predicts a 2/3 increase in stability radius per completed oscillatory cycle. Falsified if: continuous-dose equivalents produce identical or superior clinical outcomes compared to the 6-cycle oscillatory protocol.

ILLUSTRATIVE MOCK-UP — not a real run. The command axle run-protein-model and the output below do not exist in TOTOGT/AXLE; no verification of this kind was performed. The text shows the kind of check the framework would need, nothing more.

-- AXLE · RegenerativeMedicine/BrazilTOGT
-- Polylaminin + SUS oscillatory protocol verification

axle run-protein-model \
  --system polylaminin \
  --homeopathy-sus \
  --oscillatory \
  --iterations 6 \
  --scale g0-to-g33 \
  --verify dm3

→ "G6 invariants satisfied, τ=2, Separation Theorem holds,
   protein-shape regeneration from g⁰ to g³³ stable.
   Continuous dosing fails B₃ boundary check."

Brazil's polylaminin research (UFRJ, Cristália) and the SUS homeopathy-in-practice question are independent empirical programmes. The framework offers one reading of them, with predictions listed above that its authors flag as unchecked or mis-specified. It did not produce the clinical results, and nothing here shows that the operator chain explains them; the clinical findings belong to the researchers and are reported as they stand.

Acknowledgment

Tatiana Coelho de Sampaio and her team at UFRJ spent 25 years developing polylaminin — obtaining ANVISA approval, running the animal trials, conducting the human preprint study, watching patients regain movement they were told they would never have again. The mathematics in this chapter describes the geometry of what she already made work. The operator chain C → K → F → U is an explanation, not the achievement. The achievement is hers.

References

Coelho-Sampaio, T. et al. (2025). A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial. Frontiers in Veterinary Science. doi:10.3389/fvets.2025.1592687
Coelho-Sampaio, T. et al. (2024). Polylaminin in acute complete SCI. medRxiv preprint. doi:10.1101/2024.02.19.24301010
Grossi, P.N. (2026). Principia Orthogona Book 3 / main-2.tex — Chapter: Protein Shape Transformations. G6 LLC, Newark NJ.
Zenodo series: 10.5281/zenodo.19117400

Protein ShapeTransformations